Performance assessment model for guideline-recommended pharmacotherapy in the secondary prevention of coronary artery disease and treatment of left ventricular dysfunction

American Journal of Cardiology

Volumn 80, Issue 8 B, 1997, Pages

  Simpson Jr , Ross J ^a,b   Sueta, Carla A ^a,b   Boccuzzi, Stephen J ^a,c   Lulla, A ^a,c   Biggs, David ^a,b   Londhe, Anil ^a,b   Smith Jr , Sidney C ^a,b  

^a Medical Review of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; CONFERENCE PAPER; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEART LEFT VENTRICLE FAILURE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SECONDARY PREVENTION;

EID: 0343632335     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00821-7     Document Type: Conference Paper

References (24)

1. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel BJ, Russell RO, Smith EE III, Weaver WD. ACC/AHA guidelines for the management of patients with acute myocardial infarction a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Management of Acute Myocardial Infarction) . J Am Coll Cardiol. 28:1996;1328-1428.
2. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
3. Smith SC Jr, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Gould KL, Greenland P, Grundy SM, Hill MN, Hlatky MA, Houston-Miller N, Krauss RM, LaRosa J, Ockene IS, Oparil S, Pearson TA, Rapaport E, Starke RD. Preventing heart attack and death in patients with coronary disease. Circulation. 92:1995;2-4.
4. Konstam, MA, Dracup, K, Baker DW, Bottorff, MB, Brooks, NH, Dacey RA, Dunbar SB, Jackson AB, Jessup M, Johnson JC, Jones RH, Luchi, RJ, Massie BM, Pitt B, Rose EA, Rubin LJ, Wright RF, Hadorn DC. Heart Failure: Evaluation and Care of Patients with Left-Ventricular Systolic Dysfunction. Clinical Practice Guideline No. 11 (AHCPR Publication No. 994-0612).
5. Guidelines for the evaluation and management of heart failure. J Am Coll Cardiol. 25:1995;1376-1398.
6. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videk J, Cole D, Auclert L, Pauly NC, Aliot E, Persson S, Camm AJ. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;1670-1676.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
8. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 316:1987;1429-1435.
9. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Beat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
10. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left-ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
11. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EF, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left-ventricular dysfunction after myocardial infarction results of the survival and ventricular enlargement trial . N Engl J Med. 327:1992;669-677.
12. GISSI-3 effect of lisinopril and transdermal glyceral trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction . Lancet. 343:1994;1115-1122.
13. ISIS-4 a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction . Lancet. 345:1995;669-685.
14. Ambrosioni E, Borghi C, Magnani B. for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 332:1995;80-85.
15. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald. The effect of pravastatin in patients with average cholesterol levels. N Engl J Med. 3335:1996;1001-1009.
16. Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. Am J Cardiol. 76:1995;570-573.
17. Nieto FJ, Alonso J, Chambless LE, Zhong M, Ceraso M, Romm FJ, Cooper L, Folsom AR, Szklo M. Population awareness and control of hypertension and hypercholesterolemia the atherosclerosis risk in communities study . Arch Intern Med. 155:1995;677-684.
18. Giles WH, Anda RF, Jones DH, Serdula MK, Merritt RK, DeStefano F. Recent trends in the identification and treatment of high blood cholesterol by physicians progress and missed opportunities . JAMA. 269:1993;1133-1138.
19. Cohen MV, Byrne M-J, Levine B, Gutowski T, Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation. 83:1991;1294-1304.
20. Northridge DB, Shandall A, Rees A, Buchalter MB. Inadequate management of hyperlipidaemia after coronary bypass surgery shown by medical audit. Br Heart J. 72:1994;466-467.
21. Merz CN, Felando MN, Klein J. Cholesterol awareness and treatment in patients with coronary artery disease participating in cardiac rehabilitation. J Cardiopulmonary Rehabil. 16:1996;117-122.
22. Marcelino JJ, Reingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 100:1996;605-610.
23. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S. Adherence to national cholesterol education program treatment goals in postmenopausal women with heart disease. JAMA. 277:1997;1281-1286.
24. Havranek EP, Graham GW, Pan Z, Lowes B. Process and outcome of outpatient management of heart failure a comparison of cardiologists and primary care providers . Am J Man Care. 2:1996;783-789.